|0.9200||-0.1300||-12.38%||Vol 39.24K||1Y Perf -60.82%|
|Sep 22nd, 2023 16:00 DELAYED|
|- -||0.03 3.26%|
|Target Price||16.33||Analyst Rating||Hold 3.00|
|Potential %||1.68K||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||-1.84||Earnings Rating||—|
|Market Cap||10.17M||Earnings Date||10th Nov 2023|
Today's Price Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Q03 2021||-0.02||-0.26||-1 200.00|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||10th Nov 2023|
|Estimated EPS Next Report||-0.40|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||12.49K|
|Avg. Monthly Volume||14.88K|
|Avg. Quarterly Volume||68.49K|
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) stock closed at 0.92 per share at the end of the most recent trading day (a -12.38% change compared to the prior day closing price) with a volume of 39.24K shares and market capitalization of 10.17M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 0 people. Chemomab Therapeutics Ltd. CEO is Dale R. Pfost.
The one-year performance of Chemomab Therapeutics Ltd. stock is -60.82%, while year-to-date (YTD) performance is -71.25%. CMMB stock has a five-year performance of %. Its 52-week range is between 0.9999 and 5.35, which gives CMMB stock a 52-week price range ratio of -1.84%
Chemomab Therapeutics Ltd. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 0.58, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -45.48%, a ROC of -44.09% and a ROE of -48.76%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Chemomab Therapeutics Ltd., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.40 for the next earnings report. Chemomab Therapeutics Ltd.’s next earnings report date is 10th Nov 2023.
The consensus rating of Wall Street analysts for Chemomab Therapeutics Ltd. is Hold (3), with a target price of $16.33, which is +1 675.00% compared to the current price. The earnings rating for Chemomab Therapeutics Ltd. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Chemomab Therapeutics Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Chemomab Therapeutics Ltd. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.40, ATR14 : 0.07, CCI20 : -252.77, Chaikin Money Flow : 0.12, MACD : -0.04, Money Flow Index : 35.25, ROC : -14.81, RSI : 31.12, STOCH (14,3) : 7.11, STOCH RSI : 0.00, UO : 38.31, Williams %R : -92.89), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Chemomab Therapeutics Ltd. in the last 12-months were: George Adi Mor (Sold 13 800 shares of value $69 414 )
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.